7:07 AM ET
8-K
Business Update
City Therapeutics Business Update
City Therapeutics announced the first participant has been dosed in its Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease. The trial is a first-in-human study evaluating the safety, tolerability, and pharmacodynamics of the RNAi therapeutic candidate, with initial data expected in mid-2027.